HC Wainwright & Co. Maintains Buy on Puma Biotechnology, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White maintains a Buy rating on Puma Biotechnology (NASDAQ:PBYI) but lowers the price target from $8 to $7.

March 01, 2024 | 7:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Puma Biotechnology's price target was lowered from $8 to $7 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target could have a mixed impact. While the lowered target suggests a tempered outlook, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This could lead to short-term volatility as investors digest the news.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100